CHK it out! Blocking WEE kinase routs TP53 mutant cancer

Clinical Cancer Research

Volumn 20, Issue 16, 2014, Pages 4173-4175

  Bauman, Julie E ^a   Chung, Christine H ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTRANSFERASE; PROTEIN P53; UNCLASSIFIED DRUG; WEE KINASE; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA;

ARTICLE; CELL CYCLE ARREST; DISEASE ASSOCIATION; DNA DAMAGE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENETICS; HEAD AND NECK TUMOR; METABOLISM; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905973961     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0720     Document Type: Article

References (12)

1. Moser R, Xu C, Kao M, Annis J, Lerma LA, Schaupp CM, et al. Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res 2014;20:4274-88.
2. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
3. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-61. (Pubitemid 350294222)
4. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012;18:290-300.
5. Sano D, Xie TX, Ow TJ, Zhao M, Pickering CR, Zhou G, et al. Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer. Clin Cancer Res 2011;17:6658-70.
6. Gadhikar MA, Sciuto MR, Alves MV, Pickering CR, Osman AA, Neskey DM, et al. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther 2013;12:1860-73.
7. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 2001;61:8211-7. (Pubitemid 33091614)
8. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009;8:2992-3000.
9. Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 2011;17:5638-48.
10. Schellens J, Shapiro G, Pavlick A, Tibes R, Leijen S, Tolaney S, et al. Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol 29: 2011 (suppl; abstr 3068).
11. Sausville E, Lorusso P, Carducci M, Carter J, Quinn MF, Malburg L, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, incombination with gemcitabine inUSpatients with advanced solid tumors. Cancer Chemother Pharmacol 2014;73:539-49.
12. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013;15:2-8.